NCT00648674
Withdrawn
Phase 4
A Prospective, Single-Site Study to Identify and Characterize the Molecular Mechanisms of Apligraf in Non-healing Wounds of Subjects With Venous Leg Ulcers
ConditionsVaricose Ulcer
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Varicose Ulcer
- Sponsor
- Organogenesis
- Primary Endpoint
- To use the novel technology of microarrays to identify and characterize the molecular mechanisms through which Apligraf promotes healing of venous leg ulcers.
- Status
- Withdrawn
- Last Updated
- 10 years ago
Overview
Brief Summary
Single site clinical study utilizing the novel technology of microarrays to identify and characterize the molecular mechanisms through which Apligraf promotes healing of venous leg ulcers.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subject has non-infected partial or full-thickness venous leg ulcer for a duration of four weeks or greater which has not adequately responded to conventional therapy
- •Stage II or III ulcer as defined by the IAET/WOCN ulcer classification guide listed in Appendix IV.
- •Subject is female and 18 years of age or older.
- •Subject with venous leg ulcer (target ulcer) between 5 - 40 cm2 in size.
- •Sexually active females must be practicing a medically proven form of contraception during the course of the study period.
- •Subject or legal guardian must have read, understood and signed an institutional review board (IRB) approved Informed Consent Form.
- •Subject and/or legal guardian must be able and willing to follow study procedures and instructions.
Exclusion Criteria
- •Subject whose target ulcer has healed 60% or greater in area from post debridement (if applicable) Baseline Screen (Visit 1) to post debridement Day 0 (Visit 2) as determined by wound tracings.
- •Subjects who are being treated with VAC® (Vacuum Assisted Closure™) Therapy.
- •Subject has arterial disease as determined by an Ankle Brachial Index (ABI ) of \<0.
- •Subject with any systemic condition like uncontrolled diabetes mellitus (glycosylated HbA1C \> 12%), cancer (biopsy confirmed active malignancy), positive HIV test, or any disorder(s) that may compromise wound healing.
- •Subjects who are currently receiving, or have received at any time within one month prior to entry into the study, corticosteroids (\>15 mg/day), immunosuppressive agents, radiation therapy, hemodialysis or chemotherapy. Anticipated use of the above agents will exclude subjects from entry into the study.
- •Clinical vasculitis, severe rheumatoid arthritis, and other collagen vascular diseases.
- •Signs and symptoms of cellulitis or osteomyelitis.
- •Necrotic or avascular ulcer beds.
- •Venous leg ulcer with exposed bone, tendon or fascia.
- •Subject with the presence of recent infections in the area intended for treatment.
Outcomes
Primary Outcomes
To use the novel technology of microarrays to identify and characterize the molecular mechanisms through which Apligraf promotes healing of venous leg ulcers.
Time Frame: 2 weeks
Secondary Outcomes
- Determine growth factors induced by Apligraf in the wound(2 weeks)
- Safety endpoints assessed by monitoring adverse events(5 months)
- Determine how venous leg ulcer (VLU) wounds transition from chronic to acute wound healing(2 weeks)
- Examine how Apligraf rescues deficiencies of chronic wounds (VLU) and promotes transition from chronic to acute wound(2 weeks)
- Determine growth factors suppressed by Apligraf in the wound(2 weeks)
Similar Trials
Completed
Phase 4
A Post Marketing Study of Apligraf in Non-healing Wounds of Subjects With Venous Leg UlcersVenous UlcerNCT01327937Organogenesis30
Completed
Phase 1
Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamics Effect of Calcipotriol/Betamethasone Dipropionate in a New Administration Form in Subjects With Chronic Plaque Psoriasis.Psoriasis VulgarisNCT03898583LEO Pharma15
Recruiting
Not Applicable
A Single-cell Approach to Identify Biomarkers of Pulmonary Toxicity for Immune Checkpoint BlockadePneumonitis, InterstitialImmunotherapyImmune-related Adverse EventsNCT04807127Universitaire Ziekenhuizen KU Leuven60
Completed
Phase 1
The Dose Response of Prednisone on Biochemical and Clinical Makers in Adult Healthy VolunteersHealthy AdultsNCT02767089Pfizer37
Active, not recruiting
Not Applicable
The Future Management of Patients With Neoplasms of the Gastro-intestinal TractPancreatic AdenocarcinomaCholangiocarcinomaColon CancerNCT06728358Fondazione Policlinico Universitario Agostino Gemelli IRCCS300